Clinical Trials Browser

Phase 1 × Carcinoma, Neuroendocrine × Ipilimumab × Clear all

NCT06889493 2025-12-17

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

Phase 1 Recruiting

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05262556 2025-08-07

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Phase 1 Active not recruiting

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Neuroendocrine